CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Kyung-Wan Min, Bon Jeong Ku, Ji-Hyun Lee, Min-Seon Kim, Kyu-Jeung Ahn, Moon-Kyu Lee, Satoshi Kokubo, Satoshi Yoshida, Hyun-Ji Cho, Bong-Soo Cha
Diabetes Metab J. 2017;41(2):135-145.   Published online January 11, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.2.135

Excel Download

Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Diabetes & Metabolism Journal. 2017;41(2):135   Crossref logo
Link1 Link2 Link3

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
Diabetes mellitus. 2021;24(2):141-155   Crossref logo
Link1

Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study
Journal of Diabetes Investigation. 2019;10(5):1262-1271   Crossref logo
Link1 Link2 Link3

A Phase 3 Study to Assess the Efficacy and Safety of Ipragliflozin in Russian Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin
Diabetes. 2018;67(Supplement_1):   Crossref logo
Link1 Link2

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial
Journal of Diabetes Investigation. 2015;7(3):366-373   Crossref logo
Link1 Link2 Link3 Link4

Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial
Diabetes, Obesity and Metabolism. 2019;21(6):1445-1454   Crossref logo
Link1 Link2 Link3 Link4

Combination Treatment With Ipragliflozin and Metformin: A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Type 2 Diabetes Mellitus
Clinical Therapeutics. 2012;34(8):1761-1771   Crossref logo
Link1 Link2

Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
Diabetes, Obesity and Metabolism. 2019;21(10):2284-2293   Crossref logo
Link1 Link2 Link3 Link4

The Effect of Rosiglitazone and Metformin Therapy, as an Initial Therapy, in Patients with Type 2 Diabetes Mellitus (Korean Diabetes Journal 32(5):445-452, 2008)
Korean Diabetes Journal. 2008;32(6):532   Crossref logo
Link1 Link2 Link3

A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
Diabetes Research and Clinical Practice. 2018;146:240-250   Crossref logo
Link1 Link2